• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Canada
  • United Kingdom
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Coronavirus > 5 things to know this week in life sciences: Week of Jan. 11

5 things to know this week in life sciences: Week of Jan. 11

Jan. 15, 2021 by Steve Kemler and Adam Lohr

  • email
  • Twitter
  • Facebook
  • Linkedin

In this week’s roundup, we take a look at life sciences fundraising totals from 2020, which was a record year for the industry in the capital markets. Silicon Valley Bank provides a detailed look at the numbers and provides insights into what to expect this year.

Other news this week included Bluebird Bio’s announcement about splitting into two companies, the promise of quantum computing in drug design, the increased investment in biotech companies that focus on infectious disease, and how mRNA platforms offer promise for diseases beyond COVID-19.

Each week, we aggregate industry news and highlight five things you need to know about in the life sciences space. Here’s the latest.

2020 smashed capital markets records for life sciences companies

Each year, Silicon Valley Bank puts out this summary of the prior year’s capital markets activity for life sciences, health tech and health care. 2020 saw nearly $17 billion in new venture funds raised and a record $51 billion in total capital invested in health care and life sciences. Although the bank expects the totals in 2021 to be lower, it still expects north of $40 billion in new investments this year.

Bluebird Bio to split into an oncology company and a rare disease company

Bluebird Bio has been known for its work in both gene and cellular therapy research. Now, Bluebird will split into two companies, each focusing on different areas of research. The gene therapy unit will become a standalone company focused on rare diseases. The cell therapy unit will become a company focused on oncology. This is an example of the flexibility life sciences companies must exhibit as they adapt to the results of their trials and identify the best way forward. Read more in the piece linked above.

Quantum computing holds promise for drug discovery, and Google wants to help

Google’s quantum computing team and pharmaceutical company Boehringer Ingelheim are teaming up to develop new tools for drug design and discovery. Computational simulation and modeling are already a key component of the drug discovery process, but traditional computers lack the processing power to solve many of the complex challenges in this field. Quantum computing promises to solve these computationally intensive experiments more quickly and accurately.

This is one of many recent examples of the growing overlaps between tech advances in artificial intelligence, big data, quantum computing and the cutting edge of drug research.

Investments in infectious disease biotech companies extend beyond COVID-19

Historically, investments in vaccines and infectious disease research have lagged behind other areas of life sciences like oncology and work related to rare diseases. But in the wake of 2020, companies such as Affinivax have drawn additional focus and investment. Affinivax, which focuses on vaccine technologies for infectious diseases, recently raised $226 million to continue its work on a new pneumococcus vaccine to compete with Pfizer’s.

Moderna’s pipeline, beyond COVID-19

2020 was a banner year for Moderna, which quickly became a frontrunner in the race to produce COVID-19 vaccines. With an emergency use authorization from the U.S. Food and Drug Administration in place for its COVID-19 vaccine, 2021 looks like it will be an even better year for the company as mass distribution of its vaccine gets underway.

But Moderna also has a pipeline of mRNA-based drug candidates, now including two that target HIV. The company’s work further exploring the potential of mRNA is an example of the new promise that mRNA-based vaccines offer now that the COVID-19 vaccines have shown to be safe and effective.

(Bonus read: mRNA is just one of many types of RNA, and it is worth understanding the differences)

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • 5 things to know this week in life sciences: Week of Jan. 4

    In this week’s industry roundup, we look at recent drug price increases, the ongoing battle over 340B program discounts, key catalysts in Q1 for middle market biotech companies, and more.

  • 5 things to know this week in life sciences: Week of Dec. 14

    With the Food and Drug Administration approving the first COVID-19 vaccine for emergency use last week, the focus around the vaccine will start to shift toward public health messaging and how to convince tens of millions of people…

  • 5 things to know this week in life sciences: Week of Dec. 7

    This is the first installment of a new weekly roundup in which we highlight five things you need to know about in the life sciences industry. Here’s the latest, including COVID-19 vaccine news, a deal between Palantir and…

Filed Under: Coronavirus, Life Sciences Tagged With: biotech, coronavirus, Covid-19, covid-19 vaccine, life sciences, pharmaceuticals

About Steve Kemler

Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.

As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional life sciences initiatives.

In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

About Adam Lohr

Adam is an audit partner and life sciences senior analyst in RSM's cutting-edge industry eminence program. In addition to providing assurance services to his clients, he sits on RSM’s national life science team and leads the San Diego office life science practice.

His senior analyst responsibilities include advising the firm’s life sciences care clients and client servers as they work to navigate the rapidly changing industry environment. Adam regularly writes, presents and advises on capital markets, digital transformation, policy and other issues transforming life sciences. He is an instructor at the regional and national level, and is experienced in the application of ASC 606 revenue recognition for the technology and consumer products industries.

Adam has over 12 years of accounting and finance experience, serving private equity-backed and private closely held companies in the middle market. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their business.

Primary Sidebar

Other Regions

  • Canada
  • United Kingdom

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Life Science articles

5 things to know in life sciences: Week of March 1

Mar. 4, 2021

5 things to know in life sciences: Week of Feb. 22

Feb. 26, 2021

5 things to know in life sciences: Week of Feb. 15

Feb. 19, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences